Methotrexate and trimethoprim-sulphamethoxazole: Extremely serious and life-threatening combination

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 3, 2013, Pages 203-205

  Al Quteimat, O M ^a   Al Badaineh, M A ^a  

^a King Abdullah Medical City ^*  (Saudi Arabia)

Author keywords

drug interaction; methotrexate; methotrexate toxicity; pancytopenia; trimethoprim sulphamethoxazole

Indexed keywords

COTRIMOXAZOLE; METHOTREXATE; PENTAMIDINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; BINDING SITE; BONE MARROW TOXICITY; BRONCHOPNEUMONIA; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; PANCYTOPENIA; PHARMACIST; PHYSICIAN; PRACTICE GUIDELINE; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); URINARY TRACT INFECTION;

ANTI-INFECTIVE AGENTS; ANTIRHEUMATIC AGENTS; DRUG INTERACTIONS; HUMANS; METHOTREXATE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84876695671     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12060     Document Type: Review

References (27)

1. Bleyer WA,. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev, 1977; 4: 87-101.
2. Kielhofner MA,. Trimethoprim- sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions. Tex Heart Inst J, 1990; 17: 86-93.
3. Masur H,. Prevention and treatment of pneumocystis pneumonia. N Engl J Med, 1992; 327: 1853-1860.
4. Thomas MH, Gutterman LA,. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol, 1986; 13: 440-441.
5. Franck H, Rau R, Herborn G,. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol, 1996; 15: 266-270.
6. Groenendal H, Rampen FH,. Methotrexate and trimethoprim- sulphamethoxazole-a potentially hazardous combination. J Am Acad Dermatol, 1987; 17: 1055-1056.
7. Shimada T, Nishimura Y, Funada Y, et al,. A case of pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis and trimethoprim-sulphamethoxazole induced pancytopenia. Arerugi, 2004; 53: 575-581.
8. Bourré-Tessier J, Haraoui B,. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol, 2010; 37: 1416-1421.
9. Al-Awadhi A, Dale P, McKendry R,. Pancytopenia associated with low dose methotrexate therapy: a regional survey. J Rheumatol, 1993; 20: 1121-1125.
10. Ferrazzini G, Klein J, Sulh H, et al,. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukaemia. J Pediatr, 1990; 117: 823-826.
11. Beach BJ, Woods WG, Howell SB,. Influence of co-trimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol, 1981; 3: 115-119.
12. Bartha P, Bron R, Levy Y,. Fatal pancytopenia and methotrexate- trimethoprim-sulfamethoxazole interaction. Harefuah, 2004; 143: 398-400.
13. Maricic M, Davis M, Gall EP,. Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulphamethoxazole treatment. Arthritis Rheum, 1986; 29: 133-135.
14. Govert JA, Patton S, Fine RL,. Pancytopenia from using trimethoprim and methotrexate. Ann Intern Med, 1992; 117: 877-878.
15. Steuer A, Gumpel JM,. Methotrexate and trimethoprim: a fatal interaction. Br J Rheumatol, 1998; 37: 105-106.
16. Yang CH, Yang LJ, Jaing TH, et al,. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole. Int J Dermatol, 2000; 39: 621-623.
17. Chevrel G, Brantus JF, Sainte-Laudy J, et al,. Allergic pancytopenia to trimethoprim-sulphamethoxazole for pneumocystis carinii pneumonia following methotrexate treatment for rheumatoid arthritis. Rheumatology (Oxford), 1999; 38: 475-476.
18. Thomas DR, Dover JS, Camp RD,. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol, 1989; 17: 1055-1056.
19. Ng HW, Macfarlane AW, Graham RM, et al,. Near fatal drug interactions with methotrexate given for psoriasis. Br Med J (Clin Res Ed), 1987; 29: 752-753.
20. Frain JB,. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol, 1987; 14: 176-177.
21. Dan M, Shapira I,. Possible role of methotrexate in trimethoprim- sulfamethoxazole-induced acute megaloblastic anemia. Isr J Med Sci, 1984; 20: 262-263.
22. Leung WY, Lau KH,. The use of methotrexate in treatment of moderate to severe psoriasis, Hong Kong. J Dermatol Venereol, 2009; 17: 13-19.
23. Treon SP, Chabner BA,. Concepts in use of high-dose methotrexate therapy. Clin Chem, 1996; 42: 1322-1329.
24. Cadman EC, Lundberg WB, Bertino JR,. Systemic methotrexate toxicity: a pharmacological study of its occurrence after intrathecal administration in a patient with renal failure. Arch Intern Med, 1976; 136: 1321-1322.
25. Katchamart W, Bourré-Tessier J, Donka T, et al,. Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. J Rheumatol, 2010; 37: 1422-1430.
26. British Colombia Cancer Agency. Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and Rituximab, 2013.
27. Rodriguez M, Fishman JA,. Prevention of infection due to pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev, 2004; 17: 770-782.